Thermogels containing sulfated hyaluronan as novel topical therapeutics for treatment of ocular surface inflammation
Source abstract
Abstract
The development of long lasting therapeutic agents is critically important for efficient treatment of chronic diseases. We herein report a rational strategy to develop a therapeutic thermogel featured with prolonged anti-inflammatory and corneal-protective effects. Specifically, a hyaluronic acid with different sulfation degrees and an amine-terminated poly(N-isopropylacrylamide) are conjugated to achieve the thermogels. In vitro studies reveal that the thermogels are highly biocompatible to statens seruminstitut rabbit cornea cells and their anti-inflammatory properties are strongly dependent on the sulfation degree. In a rabbit model of ocular inflammation, single-dose topical administration of a thermogel formulation could repair defects in corneal epithelium (∼99% thickness restored), prevent corneal cell apoptosis (∼68.3% cells recovered), and suppress ocular surface inflammation (∼4-fold decrease) for a follow-up period of 7 days. This high treatment efficacy of the thermogel can be attributed to its potent inhibition in selectin-mediated leukocyte infiltration as well as effective corneal protection. These findings show a great promise for topical treatment of ocular inflammation and advancement of ophthalmic formulations using the bioactive thermogel as a therapeutic component that is not rapidly cleared from the eye and thus considerably reduces administration times.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ocular Surface and Contact Lens · Corneal Surgery and Treatments · Proteoglycans and glycosaminoglycans research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (79)
Show source-provided references
1. Blink rate, incomplete blinks and computer vision syndrome10.1097/OPX.0b013e31828f09a7 ↗
2. Aging and dry eye disease10.1016/j.exger.2012.03.020 ↗
3. Advancing the stimuli response of polymer-based drug delivery systems for ocular disease treatment10.1039/D0PY00919A ↗
4. Ageing and the natural history of dry eye disease: a prospective registry-based cross-sectional study10.1016/j.jtos.2020.07.003 ↗
5. The economic burden of dry eye disease in the United States: a decision tree analysis10.1097/ICO.0b013e3181f7f363 ↗
6. Dry eye, N10.1056/NEJMra1407936 ↗
7. Impact of ocular surface symptoms on quality of life in a United States veterans affairs population10.1016/j.ajo.2011.11.030 ↗
8. Analysis of inflammatory cytokines in the tears of dry eye patients10.1097/ICO.0b013e3181a16578 ↗
9. Novel liposome-based and in situ gelling artificial tear formulation for dry eye disease treatment10.1016/j.clae.2017.11.004 ↗
10. Topical cyclosporine A therapy for dry eye syndrome
11. Recent perspectives in ocular drug delivery10.1007/s11095-008-9694-0 ↗
12. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years10.1016/j.ophtha.2005.05.013 ↗
13. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes10.1001/archopht.118.11.1489 ↗
14. Role of Th17 cells in the immunopathogenesis of dry eye disease10.1038/mi.2009.21 ↗
15. Conjunctival T-cell subpopulations in Sjögren’s and non-Sjögren’s patients with dry eye
16. Sjögren’s syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium
17. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren’s syndrome keratoconjunctivitis sicca10.1076/ceyr.19.3.201.5309 ↗
18. Elevated tear interleukin-6 levels in patients with Sjögren’s syndrome10.1016/S0161-6420(98)91236-2 ↗
19. Distribution of conjunctival HLA-DR expression and the pathogenesis of damage in early dry eye10.1097/01.ico.0000157421.93522.00 ↗
20. Strain-related cytokine profiles on the murine ocular surface in response to desiccating stress10.1097/ICO.0b013e318033a729 ↗
21. Dietary lactoferrin alleviates age-related lacrimal gland dysfunction in mice10.1371/journal.pone.0033148 ↗
22. The core mechanism of dry eye disease is inflammation10.1097/ICL.0000000000000042 ↗
23. Evaluation of topical cyclosporine for the treatment of dry eye disease10.1001/archopht.126.8.1046 ↗
24. Corticosteroid-induced glaucoma: a review of the literature10.1038/sj.eye.6701895 ↗
25. TRI Microspheres prevent key signs of dry eye disease in a murine, inflammatory model10.1038/s41598-017-17869-y ↗
26. Demonstration of P-selectin expression and potential function in human corneal epithelial cells10.1016/j.exer.2018.07.018 ↗
27. Comparison of 0.1%, 0.18%, and 0.3% hyaluronic acid eye drops in the treatment of experimental dry eye10.1089/jop.2018.0032 ↗
28. Effectiveness of sodium hyaluronate eye drops in the treatment of dry eye10.1007/s00417-005-0028-1 ↗
29. Hyaluronic acid in ocular drug delivery10.1016/j.carbpol.2021.118006 ↗
30. Applications of hyaluronic acid in ophthalmology and contact lenses10.3390/molecules26092485 ↗
31. In vitro and in vivo selectin-blocking activities of sulfated lipids and sulfated sialyl compounds10.1093/intimm/10.5.569 ↗
32. Therapeutic effect of sulphated hyaluronic acid, a potential selectin-blocking agent, on experimental progressive mesangial proliferative glomerulonephritis10.1002/path.1209 ↗
33. Sulfated hyaluronic acid, a potential selectin inhibitor, ameliorates experimentally induced crescentic glomerulonephritis10.1159/000081795 ↗
34. Covalent linkage of sulfated hyaluronan to the collagen scaffold Mucograft® enhances scaffold stability and reduces proinflammatory macrophage activation in vivo
35. Modifications of hyaluronan influence the interaction with human bone morphogenetic protein-4 (hBMP-4)10.1021/bm9008827 ↗
36. A gelatin-g-poly(N-isopropylacrylamide) biodegradable in situ gelling delivery system for the intracameral administration of pilocarpine10.1016/j.biomaterials.2011.11.085 ↗
37. Preparation of thermo-responsive and injectable hydrogels based on hyaluronic acid and poly(N-isopropylacrylamide) and their drug release behaviors10.1007/BF03219073 ↗
38. Photoresponsive PEG-anthracene grafted hyaluronan as a controlled-delivery biomaterial10.1021/bm101233m ↗
39. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride10.1167/iovs.07-0720 ↗
40. Mikulicz's disease and Sjogren's syndrome
41. Development of a simple dry eye model in the albino rabbit and evaluation of some tear substitutes10.1159/000055537 ↗
42. The gene transfection efficiency of thermoresponsive N, N, N-trimethyl chitosan chloride-g-poly (N-isopropyl acrylamide) copolymer10.1016/j.biomaterials.2007.06.033 ↗
43. Stimuli-responsive, biocompatible hydrogel derived from glycogen and poly(N-isopropylacrylamide) for colon targeted delivery of ornidazole and 5-amino salicylic acid10.1039/C6PY01128D ↗
44. Synthesis of functionalized amine oligomers by free-radical telomerization of methyl methacrylate with a peculiar telogen: 2-Aminoethanethiol hydrochloride10.1002/pola.20303 ↗
45. Stimuli-sensitive hydrogel based on N-isopropylacrylamide and itaconic acid for entrapment and controlled release of Candida rugosa lipase under mild conditions10.1155/2014/364930 ↗
46. Novel thermosensitive hydrogel composites based on poly(D,L-lactide-co-glycolide) nanoparticles embedded in poly(N-isopropyl acrylamide) with sustained drug-release behavior10.1002/app.40625 ↗
47. Selective binding of C-6 OH sulfated hyaluronic acid to the angiogenic isoform of VEGF(165)10.1016/j.biomaterials.2015.10.074 ↗
48. Sulphated hyaluronic acids: a chemical and biological characterization10.1002/(SICI)1097-0126(199807)46:3<225::AID-PI45>3.0.CO;2-I ↗
49. Preparation of low-molecular-weight hyaluronic acid by ozone treatment10.1016/j.carbpol.2012.03.081 ↗
50. Production and characterization of bacterial cellulose membranes with hyaluronic acid from chicken comb10.1016/j.ijbiomac.2017.01.077 ↗
51. Thermoresponsive poly(N-isopropylacrylamide-co-dimethylaminoethyl methacrylate) microgel aqueous dispersions with potential antimicrobial properties10.3390/polym11040606 ↗
52. Evaluation of surface charge shift of collagen fibrils exposed to glutaraldehyde10.1038/s41598-018-28293-1 ↗
53. Self-assembled thermoresponsive nanostructures of hyaluronic acid conjugates for osteoarthritis therapy10.1039/C7NR07614B ↗
54. Incorporation of sulfated hyaluronic acid macromers into degradable hydrogel scaffolds for sustained molecule delivery10.1039/C3BM60227C ↗
55. Thermoreversible hyaluronic acid-PNIPAAm hydrogel systems for 3D stem cell culture10.1002/adhm.201800225 ↗
56. Hyaluronan/collagen hydrogels with sulfated hyaluronan for improved repair of vascularized tissue tune the binding of proteins and promote endothelial cell growth10.1002/mabi.201700154 ↗
57. Improvement of the digestibility of sulfated hyaluronans by bovine testicular hyaluronidase: a UV spectroscopic and mass spectrometric study10.1155/2014/986594 ↗
58. Assessment of cytotoxicity of (N-isopropyl acrylamide) and poly(N-isopropyl acrylamide)-coated surfaces10.1186/1559-4106-8-19 ↗
59. Bioengineered human corneal endothelium for transplantation10.1001/archopht.124.10.1441 ↗
60. Cytoprotective effects of hyaluronic acid and carbomer 934P in ocular surface epithelial cells
61. Biocompatibility and enzymatic degradation studies on sulphated hyaluronic acid derivatives10.1016/S0142-9612(97)00089-6 ↗
62. Anti-inflammatory effects of hyaluronan in arthritis therapy: not just for viscosity10.2147/IJGM.S5495 ↗
63. Hyaluronan, a crucial regulator of inflammation10.3389/fimmu.2014.00101 ↗
64. Novel sulfated polysaccharides disrupt cathelicidins, inhibit RAGE and reduce cutaneous inflammation in a mouse model of rosacea
65. Anti-inflammatory effects of sulfatides in selectin-dependent acute lung injury10.1093/intimm/7.7.1107 ↗
66. The challenge of dry eye diagnosis10.2147/OPTH.S1496 ↗
67. Dry eye with only decreased tear break-up time is sometimes associated with allergic conjunctivitis10.1016/S0161-6420(95)31024-X ↗
68. Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping10.1089/jop.2015.0054 ↗
69. Rose bengal staining as an assessment of ocular surface damage and recovery in dry eye disease-a review10.1016/j.clae.2013.07.008 ↗
70. The diagnosis and management of dry eye: a twenty-five-year review10.1097/00003226-200009000-00009 ↗
71. Rebamipide ophthalmic solution modulates the ratio of T helper cell 17/regulatory T cells in dry eye disease mice
72. In vitro measurement of rabbit corneal epithelial thickness using ultrahigh resolution optical coherence tomography10.1111/j.1463-5224.2005.00345.x ↗
73. Apoptosis of ocular surface cells in experimentally induced dry eye10.1167/iovs.02-0581 ↗
74. Research on the stability of a rabbit dry eye model induced by topical application of the preservative benzalkonium chloride
75. Efficacy of osmoprotectants on prevention and treatment of murine dry eye10.1167/iovs.13-12081 ↗
76. Diclofenac protects cultured human corneal epithelial cells against hyperosmolarity and ameliorates corneal surface damage in a rat model of dry eye10.1167/iovs.13-13850 ↗
77. A murine model of dry eye induced by topical administration of erlotinib eye drops
78. Advances in the diagnosis and treatment of dry eye10.1016/j.preteyeres.2020.100842 ↗
79. Sleep deprivation induces dry eye through inhibition of PPARα expression in corneal epithelium10.1167/iovs.18-24504 ↗